A Comparative Analysis of Low Dose Grafalon <sup>®</sup> Versus Thymoglobuline <sup>®</sup> as Serotherapy in Hematopoietic Stem Cell Transplant in Pediatric and Young Adult Population
Garima NirmalCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaGaurav KharyaCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaRavi ShankarCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaSaksham SinghCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaSubhasish PaulCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaMohit ChoudharyDepartment of Transfusion Medicine, Indraprsatha Apollo Hospital, Delhi, IndiaVaibhav ChadhaCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaK.Z. IskandarovDepartment of Pediatric Hematology Oncology & BMT, National Children’s Medical Centre, Tashkent, UzbekistanSayitov BegaliDepartment of Pediatric Hematology Oncology & BMT, National Children’s Medical Centre, Tashkent, UzbekistanAtish BakaneCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, IndiaGoutomi ChatterjeeCentre for Bone Marrow Transplant & Cellular Therapy, Indraprastha Apollo Hospital, Delhi, India
ABI
Аннотация
tended to have better OS, decreased incidence of acute grade III-IV GvHD, and extensive cGVHD. There was no difference in engraftment kinetics, PGF, and immune reconstitution between 2 cohorts of serotherapy.
Перевод пока недоступен
Темы
Идентификаторы
Цитирования и источники
Цитирований: 0Использованных источников: 20
Показатели — AkademScholar · Скоро